Xiehe Yixue Zazhi (Mar 2025)

Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)

  • Society of Gynecologic Oncology, Chinese Medical Association,
  • Branch of Colposcopy and Cervical Pathology, China Healthy Birth Science Association,
  • Professional Committee on Cancer Prevention and Control, Chinese Preventive Medicine Association,
  • Specialized Committee on Cervical Cancer Prevention and Control Research, China Maternal and Child Health Research Association,
  • National Collaborative Group for Cervical Cancer Prevention and Treatment, China Cancer Foundation,
  • Committee on Cervical Cancer, China Anti-Cancer Association,
  • Branch of Obstetric and Gynecological Health Medicine, China International Exchange and Promotive Association for Medical and Health Care

DOI
https://doi.org/10.12290/xhyxzz.2025-0246
Journal volume & issue
Vol. 16, no. 2
pp. 350 – 360

Abstract

Read online

Prophylactic human papilloma virus (HPV) vaccination is an effective strategy to prevent HPV infection and reduce the incidence of HPV-related diseases.Current clinical trials and real-world studies globally have demonstrated that prophylactic HPV vaccines are safe, immunogenic, and exhibit robust protective efficacy and effectiveness.Priority vaccination is recommended for females aged 9-26 years, with a focus on girls aged 9-14 years.Additionally, vaccination is advised for females aged 27-45 years and males aged 9-26 years to promote gender-neutral prevention strategies.Prophylactic HPV vaccination is also recommended for high-risk and special populations, including individuals with HPV infection or cytological abnormalities, those with a history of HPV-related lesions, genetically susceptible populations, individuals with high-risk lifestyle behaviors associated with cervical cancer, and immunocompromised patients.Regular cervical cancer screening remains essential post-vaccination.

Keywords